Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
Biodesix, Inc., a data-driven diagnostic solutions company with a focus in lung disease, appoints Dr. Jon Faiz Kayyem to the board of directors.
Spesana and Biodesix Inc. announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management.
Biodesix, Inc. announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify ICI treatment response in patients with advanced NSCLC.
Biodesix, Inc. today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.
Biodesix, Inc. today announced that the company will co-present with Genentech three posters at SITC Nov. 10–14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.
Biodesix, Inc. today announced CEO Scott Hutton will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.
Biodesix, Inc. today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15.
Biodesix, Inc., a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference.
Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.